<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303899</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-2014-002</org_study_id>
    <nct_id>NCT02303899</nct_id>
  </id_info>
  <brief_title>Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma</brief_title>
  <official_title>A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, monocentric study of the combination of gemcitabine and imatinib mesylate
      in pemetrexed-pretreated patients with MPM expressing PDGFR-beta and/or C-kit by
      Immunohistochemistry (IHC). Treatment will be done until disease progression, or patient
      refusal or withdrawal of patient consent, or unacceptable toxicity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pemetrexed-pretreated patients with MPM expressing PDGFR-beta and/or C-kit by IHC will
      receive chemotherapy as follow :

        -  Gemcitabine 1000 mg/m2, i.v., days 3 and 10 of a 21-days schedule;

        -  Imatinib mesylate 400 mg/die orally on days 1-5 and 8-12 of a 21-days schedule.

      Treatment repeats every 21 days in the absence of disease progression, patient refusal or
      withdrawal of patient consent, or unacceptable toxicity.

      The molecular profile of patients enrolled will be evaluated with Ion Personal Genome Machine
      (PGM) Torrent Next-generation Sequencing platform in order to individuate potential
      predictive biomarkers and to improve the understanding of the molecular biology of these rare
      tumors. A correlation among the molecular profiles identified, clinical characteristics, and
      survival data of patients will be done
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti-tumor activity of Imatinib mesylate in combination with Gemcitabine</measure>
    <time_frame>12 weeks</time_frame>
    <description>assess the anti-tumor activity of Imatinib mesylate in combination with Gemcitabine, in terms of 3-months progression-free survival (PFS) rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anti-tumor activity of Imatinib mesylate in combination with Gemcitabine in terms of Response Evaluation Criteria In Solid Tumors (RECIST) criteria</measure>
    <time_frame>16 weeks</time_frame>
    <description>assess anti-tumor activity of Imatinib Mesylate (IM) in combination with GEM, in terms of objective response rate according to RECIST criteria (Modified RECIST criteria for MPM), and duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-tumor activity of Imatinib mesylate in combination with Gemcitabine in terms of overall survival (OS).</measure>
    <time_frame>30 months</time_frame>
    <description>assess anti-tumor activity of IM in combination with GEM, in terms of overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profile of the combination according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3</measure>
    <time_frame>16 weeks</time_frame>
    <description>determine the safety profile of the combination according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>molecular profile of patients</measure>
    <time_frame>baseline</time_frame>
    <description>evaluate the molecular profile of patients enrolled with Ion PGM Torrent Next-generation Sequencing platform correlating the molecular profiles identified with clinical characteristics and survival data of patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Mesothelioma, Malignant</condition>
  <arm_group>
    <arm_group_label>Gemcitabine &amp; Imatinib mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 1000 mg/m2, i.v., days 3 and 10 of a 21-days schedule; Imatinib mesylate 400 mg/die orally on days 1-5 and 8-12 of a 21-days schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>infusion drug</description>
    <arm_group_label>Gemcitabine &amp; Imatinib mesylate</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate</intervention_name>
    <description>oral drug</description>
    <arm_group_label>Gemcitabine &amp; Imatinib mesylate</arm_group_label>
    <other_name>Glivec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age of &gt; 18 years.

          2. Histologically proven malignant mesothelioma of the pleura or of the peritoneum,
             expressing PDGFR-beta and/or C-kit by immunohistochemistry.

          3. Locally advanced disease, unsuitable for curative surgical resection, or metastatic
             disease.

          4. Confirmed progression of the disease according to modified RECIST-criteria, documented
             after a pemetrexed-based chemotherapy.

          5. Eastern Cooperative Oncology group (ECOG) Performance Status of 0, 1 or 2.

          6. Life expectancy of at least 3 months.

          7. Written informed consent.

        Exclusion Criteria:

          1. Co-existing tumors of different histologic origin, except non melanomatous localized
             skin cancer and/or in situ cervical carcinoma.

          2. A history of earlier tumors of different histologic origin being in complete remission
             for less than 5 years.

          3. Unresolved toxicity from prior antitumor treatment(s).

          4. Primary peritoneal mesothelioma.

          5. Any of the following abnormal baseline hematological values:

               -  Hb &lt; 9 g/dL

               -  White blood count (WBC) &lt; 3 x 109/L

               -  Neutrophils &lt; 1.5 x 109/L

               -  Platelets &lt; 100 x 109/L

               -  Serum bilirubin &gt; 2.5 mg/dL

               -  Alanine transaminase (ALAT) and Aspartate transaminase (ASAT) &gt; 3 x upper normal
                  limit (UNL) (unless due to liver metastases)

               -  Serum creatinine &gt; 1.5 mg/dL.

          6. Symptomatic and/or unstable pre-existing brain metastases. To be enrolled in the
             study, subjects must have confirmation of stable disease by MRI or computer tomography
             (CT) scan within 4 weeks from day 1 of cycle 1 of treatment and have central nervous
             system (CNS) metastases well controlled by steroids, anti - epileptics or other
             symptom-relieving medications.

          7. Clinically relevant cardiovascular disease, i.e., myocardial infarction or other
             severe coronary artery diseases within the prior 6 months, cardiac arrythmia requiring
             medication, uncontrolled hypertension, overt cardiac failure or non compensated
             chronic heart disease in New York Heart Association (NYHA) class II or more.

          8. History of psychiatric disabilities, potentially interfering with the capability of
             giving adequate informed consent.

          9. Pregnant or lactating women or inability/unwillingness to practice a medically
             approved method of contraception during study period (including 3 months following the
             end of treatment)

         10. Uncontrolled active infections.

         11. Any condition which, in the judgement of the Investigator, would place the patient at
             undue risk or interfere with the results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44.</citation>
    <PMID>12860938</PMID>
  </reference>
  <reference>
    <citation>Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006 Mar 20;24(9):1443-8.</citation>
    <PMID>16549838</PMID>
  </reference>
  <reference>
    <citation>Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008 Feb;19(2):370-3. Epub 2007 Dec 20.</citation>
    <PMID>18156144</PMID>
  </reference>
  <reference>
    <citation>Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008 Jul;3(7):756-63. doi: 10.1097/JTO.0b013e31817c73d6.</citation>
    <PMID>18594322</PMID>
  </reference>
  <reference>
    <citation>Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev. 2010 Feb;36(1):24-32. doi: 10.1016/j.ctrv.2009.09.003. Epub 2009 Oct 29. Review.</citation>
    <PMID>19879055</PMID>
  </reference>
  <reference>
    <citation>Pietras K, Ostman A, Sjöquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001 Apr 1;61(7):2929-34.</citation>
    <PMID>11306470</PMID>
  </reference>
  <reference>
    <citation>Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin CH, Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002 Oct 1;62(19):5476-84.</citation>
    <PMID>12359756</PMID>
  </reference>
  <reference>
    <citation>Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, McSheehy P, Wartmann M, Ostman A. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3779-87.</citation>
    <PMID>14506171</PMID>
  </reference>
  <reference>
    <citation>Garlepp MJ, Leong CC. Biological and immunological aspects of malignant mesothelioma. Eur Respir J. 1995 Apr;8(4):643-50. Review.</citation>
    <PMID>7664867</PMID>
  </reference>
  <reference>
    <citation>Langerak AW, van der Linden-van Beurden CA, Versnel MA. Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim Biophys Acta. 1996 Feb 7;1305(1-2):63-70.</citation>
    <PMID>8605252</PMID>
  </reference>
  <reference>
    <citation>Pogrebniak HW, Lubensky IA, Pass HI. Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapies? Surg Oncol. 1993 Aug;2(4):235-40.</citation>
    <PMID>8252214</PMID>
  </reference>
  <reference>
    <citation>Klominek J, Baskin B, Hauzenberger D. Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. Clin Exp Metastasis. 1998 Aug;16(6):529-39.</citation>
    <PMID>9872600</PMID>
  </reference>
  <reference>
    <citation>Sawyers C. Targeted cancer therapy. Nature. 2004 Nov 18;432(7015):294-7. Review.</citation>
    <PMID>15549090</PMID>
  </reference>
  <reference>
    <citation>Shih AH, Holland EC. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 2006 Feb 8;232(2):139-47. Epub 2005 Aug 31. Review.</citation>
    <PMID>16139423</PMID>
  </reference>
  <reference>
    <citation>Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol. 2003 Jan 31;36(1):49-59. Review.</citation>
    <PMID>12542975</PMID>
  </reference>
  <reference>
    <citation>Johnson MD, Okedli E, Woodard A, Toms SA, Allen GS. Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J Neurosurg. 2002 Sep;97(3):668-75.</citation>
    <PMID>12296652</PMID>
  </reference>
  <reference>
    <citation>Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2007 Jan;59(1):149-50. Epub 2006 Apr 25.</citation>
    <PMID>16636799</PMID>
  </reference>
  <reference>
    <citation>Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol. 2001 Aug;116(2):253-62.</citation>
    <PMID>11488073</PMID>
  </reference>
  <reference>
    <citation>George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol. 2001 Oct;28(5 Suppl 17):27-33. Review.</citation>
    <PMID>11740804</PMID>
  </reference>
  <reference>
    <citation>Taylor JR, Brownlow N, Domin J, Dibb NJ. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene. 2006 Jan 5;25(1):147-51.</citation>
    <PMID>16170366</PMID>
  </reference>
  <reference>
    <citation>Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer. 2005 Oct;50(1):83-6.</citation>
    <PMID>15951053</PMID>
  </reference>
  <reference>
    <citation>Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S, Tassi G, Favoni R, Gaudino G, Mutti L. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax. 2007 Aug;62(8):690-5. Epub 2007 Feb 20.</citation>
    <PMID>17311837</PMID>
  </reference>
  <reference>
    <citation>Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, Mutti L, Gaudino G. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res. 2008 Jan 15;14(2):541-8. doi: 10.1158/1078-0432.CCR-07-1388.</citation>
    <PMID>18223230</PMID>
  </reference>
  <reference>
    <citation>George S, Desai J, Paul Eder J, Manola J, Ryan DP, Appleman LJ, Demetri GD. Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. Eur J Cancer. 2006 May;42(7):864-70. Epub 2006 Feb 28.</citation>
    <PMID>16503137</PMID>
  </reference>
  <reference>
    <citation>Ali Y, Lin Y, Gharibo MM, Gounder MK, Stein MN, Lagattuta TF, Egorin MJ, Rubin EH, Poplin EA. Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res. 2007 Oct 1;13(19):5876-82.</citation>
    <PMID>17908982</PMID>
  </reference>
  <reference>
    <citation>Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004 Feb;15(2):257-60.</citation>
    <PMID>14760119</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>not planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

